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ADVANCES AT ACSI: HIGH CURRENT TR19 AND THE NEW TR24 
CYCLOTRON CAPABILITIES AND OPERATIONAL EXPERIENCE
Alexander Zyuzin, Russell Watt, Bill Gyles, Karl Erdman, Erik J. van Lier
Advanced Cyclotron Systems Inc., Vancouver, BC, Canada
Over the past few years ACSI has successfully automated the TR19 cyclotron operation, 
has demonstrated the feasibility and reliability of the high current (300 µA) TR19 and completed 
the development of a new 24 MeV cyclotron — TR24.
High current, fully automated TR19. In January 2009 Advanced Cyclotron Systems Inc. (ACSI) 
commissioned first fully automated, high current TR19 cyclotron. With over three years in 
routine operation, this new cyclotron is operating with 100% uptime, no production days were 
missed. Typical production schedule is 5 day per week, 2–3 production runs production with 
2–3 hours irradiation each. Over 30 Ci of F-18 is produced routinely in a single run. Over 100 
Ci of F-18 was produced daily for several months of higher demand. Typically, the current on 
target is 2 x 100 2x100 µA, however, the cyclotron is operated at 2 x 125 µAmp current on 
targets (limitation by target capacity) when higher production is required, with total extracted 
current of approximately 300 µAmp.
In factory, the high current TR19 was tested at 1MeV up to 600 µA. Three additional high cur-
rent TR19 will be installed this year. One of them will be installed at the Institute of Physics and 
Nuclear Engineering in Bucharest. This machine will be equipped with an external beamline, 
which will allow it to fully take advantage of the high currents.
Bridging the gap. TR24 cyclotron
Typical Biomedical cyclotrons have energy range from 11 MeV to 19 MeV, while high energy 
commercial cyclotrons have > 30 MeV. In the recent years many research labs expressed 
interest in widening spectrum of their research capacity by complementing production of PET 
radioisotopes with a variety of so-called research isotopes, including classical SPECT isotopes. 
A number of regional radioisotope suppliers were also exploring business models which included 
production and supply of not only fluorine-18 based compound, but also of a variety of other 
isotopes, included, but not limited to I-123, Ge-68, In-111, Ga67. 
In the last two years the nuclear medicine community started researching alternatives to 
the existing reactor based supply of Tc-99m. In 2009 ACSI, in collaboration with a number 
of Canadian Universities and Research Centers started exploratory work directed at the de-
velopment of commercially viable technology for the production of Tc-99m using a medium 
Automated high current TR19 features: Cyclotron and Targetry Capacity:
Preset machine wake-up Extracted current > 300 mAmp
One-button fully automated operation Variable energy 14 MeV to 19 MeV 
4-jaw collimation with operator predetermined 
collimator spill ratio 
Beam on target 2 x 150 µAmp 
(> 300 µAmp in external beam line)
Real time “Beam-Target” alignment F18 over 30 Ci in production run
Dual beam split ratio adjustment 
from 1:100 to 50:50 N13 in target ammonia > 1 Ci
Current stability ± 5% C11 > 4 Ci, 20–40 Ci/nmol
Automated magnetic field compensation Solid targetry
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energy cyclotron. This coincided with the design completion of new medium energy, high 
current cyclotron. TR24, is based on the TR19 platform and utilizes main components and 
sub-systems of TR19 and TR30 cyclotrons. In 2010, the first TR24 was manufactured and 
400 µA were achieved during factory testing. This cyclotron has rapidly become our best 
seller, with 10 TR24 orders received in the last two years.  In 2010, ACSI was awarded $11 
M through the Non-reactor-based Isotope Supply Contribution Program (NISP) to commer-
cialize cyclotron production of Tc-99m using high current TR24 cyclotrons. The high cur-
rent TR24 cyclotrons will be operational in 2012 at two pilot sites: University of Sherbrooke 
and University of Alberta, Edmonton.  Both sites will supply copious amounts of FDG and 
demonstrate the feasibility of cyclotron production of Tc-99m.The Sherbrooke cyclotron 
was installed in February and is now being commissioned. This cyclotron is equipped with 
two external beam lines and a high current, 500 uAmp, solid target station. Test results and 
first operational experiences will be reported.
TR24 Cyclotron specifications:
Extracted current: > 500 mAmp
Energy: 16 MeV to 24 MeV (variable)
Magnet orientation: Horizontal
Extraction: Dual, single or multiple extraction foils
Beam lines: Up to 6 and/or 4-position target selectors mounted on the cyclotron
Targetry: Full range of liquid, gas and solid targetry for PET and SPECT 
  radioisotope productio
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FULLY AUTOMATED PROCESSES AND INNOVATIVE m-PET 
APPLICATIONS OF NOVEL LABELLED SUBSTRATES
G Brini, A Caracci, S Caria, M Fulvi
Nuclear Specialists Associated S.r.l Via Pontina vecchia Km 33,800, 00040 Ardea (Rm) Italy
[18F]-Fluorodeoxyglucose ([18F]-FDG) is the most common radiotracer used in PET studies in 
oncology. In recent years the synthesis of new and long-lived beta emitters compounds has de-
monstrate the usefulness of PET imaging as non-invasive diagnostic tool also in non oncologic 
field. 
The production of radionuclides is based on a low-energy (p, n) reaction at a small-sized (16.5 
MeV) GE PETtrace 10 Ci cyclotron, while the radiotracers production is performed using dif-
ferent automatic modules and different hot cells. Due to the fully automated process, from the 
radioisotopes production to the synthesis and purification of the final products, the operators are 
completely shielded from radiation.
In this work we describe the µ-PET preclinical applications of the fully automated synthesis of 
[64Cu]-Copper (t1/2 = 12.7 hours) and [
124I]-Iodine (t1/2 = 4.18 days) labelled substrates and of 
[18F]-Fluorine (t1/2 = 110 min) based tracers, such as [
18F]-Fluorothymidine, [18F]-FluoroDOPA, 
[18F]-Sodium Fluoride and [18F]-Fluorocholine.
A wide variety of substrates, such as functionalized chelators, peptides, antibodies and other 
biologically relevant small molecules, can be radiolabeled due to the well-established chemistry of 
[64Cu]-Copper and [124I]-Iodine. Moreover decay properties and long half-life of [64Cu]-Copper and 
[124I]-Iodine permits the labeled molecules to be imaged and studied over a longer time period.
The radiopharmaceutical 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine ([18F]-FDOPA) 
has great interest in neuro-oncology because it is an aminoacid-analogue used to evalu-
ate presynaptic dopaminergic activity. The bone imaging probe with [18F]-Sodium Fluoride 
has been used to evaluate both benign and malignant skeletal disorders. The radiotra-
cers [18F]-Fluorocholine and [18F]-Fluorothymidine have been developed as PET tracers to 
image proliferation in vivo with two different molecular pathways.
In several preclinical studies we evaluate that the µ-PET applications give the possibility 
to monitor different experimental situations thanks to the wide variety of radiotracers avai-
lable. Due to their long half-life, [64Cu]-Copper and [124I]-Iodine are used to radiolabelled 
molecules and monitor their biodistribution at different time points. Radiolabelling of an-
tibodies with [124I]-Iodine and [64Cu]-Copper was performed to evaluate the capability of 
radiotracers to bind and accumulate into a district of interest from 4 to 120 hours (in case of 
radio-iodination) and from 1 to 22 hours (in case of Copper coordination) after the injection. 
Data obtained from µ-PET analysis allows us to visualize the binding between molecules, 
while data elaboration permits the rate quantification of radiotracer uptake in the district of 
interest.
Due to the short half life of [18F]-Fluorine, the fluorine radiotracers are not used to monitor 
the biodistribution over a long time period, but are employed in other PET-studies. [18F]-
-NaF radiopharmaceutical was used to monitor the osseous tissue regeneration induced 
by stem cells associated to different biomaterials. The bone regeneration induced by the 
graft, implanted in rat calvarial defects, was monitored from 2 to 12 week after the implant.
[18F]-FCh and [18F]-FLT PET was used to observe the cell proliferation in a luciferase trans-
genic mouse model, previously analyzed through in vivo bioluminescence imaging. [18F]-
-FDOPA-PET was used to evaluate the therapeutic efficacy of a treatment employeed for the 
F98 rat glioma growth, an anaplastic tumour characterized by unfavourable clinical outcome. 
Our PET-data showed a linear reduction of the tumour growth in the experimental group.
In conclusion in vivo µ-PET analysis performed with short and long half life isotopes labelled 
compounds represents a safe and innovative diagnostic and non-invasive system that allows the 
study of several physiologic processes in small animal models reducing the time of experiment 
and the number of animals.
Key words: fully automated synthesis; [64Cu]-Copper; [124I]-Iodine; [18F]-Fluorine; µ-PET Imaging
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POLYMER SCINTILLATOR DETECTORS FOR TOF-PET WITH LARGE 
LONGITUDINAL FIELD OF VIEW
P Moskal, T Bednarski, A Heczko, M Kajetanowicz, Ł Kapłon, A Kochanowski, 
G Konopka-Cupiał, G Korcyl, W Krzemień, K Łojek, W Migdał, M Molenda, S Niedźwiecki, 
P Salabura, M Silarski, A Słomski, J Smyrski, Z Rudy, J Zdebik, M Zieliński
Jagiellonian University, Cracow, Poland
In this contribution we present a concept of the large acceptance detector systems based on 
the organic scintillators which in the future may allow for simultaneous diagnostic of large frac-
tion of the human body. Novelty of the concept lies in employing predominantly the timing of 
signals instead of their amplitudes. The time resolution obtainable with plastic scintillators may 
be better than 100 ps [1] also for large detectors [2], and plastic scintillators can be produced 
easily in variety of shapes and dimensions. 
One of the investigated detector concepts [3, 4] (called strip-PET) is shown schematically in Fig. 
1. The strip-PET test chamber may be built from strips of organic scintillator forming a cylinder. 
Light signals from each strip are converted to electrical signals by two photomultipliers placed 
at opposite edges of the strip. The time difference between signals from both ends of the 
strip is used in order to determine the impact position of the gamma quantum and the time 
of the interaction of the gamma quantum in the strip is calculated as an arithmetic mean of 
the times measured on both edges of the scintillator. In the thin plastic scintillator strips the 
light signal propagates at about one-half of the speed of light in vacuum (c/2). Thus for the FWHM
(Dt) equal to 70 ps the resolution of the position determination along the scintillator strip would 
amount to FWHM(Dl) ≈ 0.5 cm and the resolution in the determination of the annihilation point 
along line-of-response would be equal to FWHM(Dx) ≈ 0.7 cm. In particular, the last feature 
makes the solution very promising. 
The plastic scintillators were so far not considered as potential sensors for PET detector due 
to their low density and small atomic number of elements constituting the material. The pro-
bability that two annihilation quanta react independently in e.g. 2.5 cm thick layer is about 16 
times smaller for the plastic detector than in the detector made of LSO crystals. However, the 
aforementioned detector concept allows to compensate for the low efficiency. Mainly because: 
i) In the 3D mode the geometric acceptance of e.g. one meter long chamber will increase on 
average by a factor of about five in the comparison to the present PET detectors. This feature in 
combination with the five times larger longitudinal field of view causes that about 25 times more 
pairs of annihilation quanta will reach the detectors. Thus, the signal rate of an individual photo-
multiplier will be similar as in the currently produced PET scanners, but signals will be more than 
ten times shorter; ii) Improvement of TOF resolution from ~600 ps to ~70 ps would improve 
Fig. 1. (left) Scheme of the strip-PET diagnostic chamber. This solution permits for extension of the size of 
the scanner without a significant increase of costs. (right) Pictorial description of strip-PET concept. The hit 
position versus the center of the scintillator (Dl) is determined based on time difference measured on both 
sides of the scintillator strip, and the position (Dx) along the line-of-response is determined from time diffe-
rence measured between two modules
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the signal to noise ratio by a factor of about eight [5]. These two effects would compensate the 
smaller efficiency, which in addition can also be increased by using several layers of the cylinder. 
Additionally: a longitudinal field of view would be more than five times larger with respect to 
present PET detectors allowing for imaging of the head and whole torso simultaneously. In the 
case of current PET scanners such image requires performance of ten independent measure-
ments. Thus, for the whole body examination with such large detector, while leaving the current 
dose of radio-pharmaceutical unchanged, one can gain another factor of ten on statistics of 
registered events. More detailed description of the strip-PET concept and its comparison with 
the present state-of-art solutions, as well as the second new detector concept [3, 4] which gi-
ves a possibility for measuring the depth of interaction (DOI), will be presented and discussed.
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SIMPLE PROCEDURE OF DOTATATE LABELLING WITH CYCLOTRON 
PRODUCED 44SC AND 43SC
Seweryn Krajewski1, Izabela Cydzik2, Kamel Abbas2, Antonio Bulgheroni2, Federica Simonell2, 
Agnieszka Majkowska-Pilip1, Aleksander Bilewicz1
1Institute of Nuclear Chemistry and Technology, Warsaw, Poland
2European Commission’s Joint Research Centre, Institute for Health and Consumer Protection, Ispra Italy
Objectives: Two scandium isotopes, 44Sc and 43Sc, are prospective radionuclides for diagnostic 
imaging. 44Sc (t1/2 = 3.92 h) and 
43Sc (t1/2 = 3.89 h) are ideal b
+-emitters in PET diagnosis. They 
can be used as an alternative to 68Ga, because they have got better nuclear properties and form 
complexes of structure similar to those of 90Y and 177Lu, what is important in planning radionu-
clide therapy [1]. 44Sc can be obtained from 44Ti/44Sc generator. Unfortunately, prohibited cost 
of production (c.a. 500 000 $ for 1 GBq) and limited availability of the long-lived 44Ti complicate 
further development in the 44Sc-radiolabeled compounds [2]. The promising method for 44Sc 
production is irradiation of 44Ca target in small cyclotrons. The aim of our work was to optimize 
the parameters of 44CaCO3 irradiation. The second aim was to develop a simple procedure of 
44Sc separation from the calcium target and labelling of the DOTATATE. These results were 
transferred on 43Sc production from natural calcium carbonate in reaction 40Ca(a,p)43Sc.
Methods: In the present work, we used highly enriched 44CaCO3 (Isoflex, Russia) and super pure 
natCaCO3 (Merck). The irradiations were performed with the Scanditronix MC 40 cyclotron of the 
Joint Research Centre (Ispra, Italy). 44CaCO3 targets of 2 mg in form of dry powder were irradiated 
by protons in the energy range from 5.5 to 23 MeV for cross section calculations. The activity of the 
samples was measured with high resolution γ-ray spectrometers. 
5–10 mg of the 44CaCO3 target and 20 mg of the 
natCaCO3 target were irradiated for labelling 
experiments. The target was dissolved in 1 ml of 0.1 M HCl. Then, the solution was passed 
through a column filled with iminodiacetic resin Chelex 100. After adsorption of 44Sc, the column 
was washed with 0.01 M HCl and the effluent containing enriched calcium was collected for 
further irradiations. The 44Sc was eluted with 1 M HCl in 0.5 ml fractions.
44Sc-DOTATATE was synthesised with different amounts of the peptide and in different pH in 
acetate buffer. The solution was heated for 30 min at 95°C. The same procedure was used for 
43Sc-DOTATATE synthesis.
Results: The analysis of the results obtained from optimization studies shows that in the proton 
energy range of 9-10 MeV on the target, the amount of 44Sc reaches the maximum with a minimum 
production of 44mSc impurity that is estimated to (0.16%). The 44Sc activity obtained after irradiation 
of 5 mg target was around 40 MBq for 1 h irradiation and 10 µA protons current, while 43Sc activity 
obtained of 20 mg target was 16 MBq for 2 h irradiation and 0.3 µA protons current.
The separation with Chelex 100 resin is very good. More than 60% of 44Sc activity was eluted with 1 M 
HCl in three initial 0.5 ml fractions. The level of Ca2+ in 44Sc reaction vials was less than 1 ppm. First 
experiments on the recovery of the calcium target showed that up to 50% of 44Ca could be recovered.
We received high yield of labelling DOTATATE with 44Sc and 43Sc, for 15 nmol it is higher than 99%. 
The target was recovered, irradiated and 44Sc was separated with Chelex 100 resin and DOTATATE 
was labelled with the yield of 99.5%. We checked the possibility of 44Sc-DOTATATE synthesis without 
calcium separation and using C18 Sep-Pak column for purification of the labelled bioconjugate.
Conclusions: The low-energy irradiation of 44Ca gives opportunity to produce GBq activity 
levels of 44Sc. The proposed separation process of 44Sc and 43Sc from calcium target is simple 
and fast. The obtained 44Sc and 43Sc can be used instead of 68Ga in PET diagnosis and planning 
radionuclide receptor therapy with 177Lu- and 90Y. The synthesis and purification procedure of 
44,43Sc-DOTATATE can be simplified using C18 Sep-Pak columns.
Research Support: This study was supported by Institute of Nuclear Chemistry and Technology 
in Warsaw, Poland and by European Commission’s Joint Research Centre in Ispra, Italy.
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COMPTON IMAGING WITH LIQUID XENON AND 44SC: RECENT 
PROGRESS TOWARD 3 GAMMA IMAGING
T Oger, WT Chen, JP Cussonneau, J Donnard, S Duval, J Lamblin, O Lemaire, 
AF Mohamad Hadi, P Le Ray, E Morteau, L Scotto Lavina, J S Stutzmann, D Thers
SUBATECH, UMR 6457, Ecole des Mines de Nantes, CNRS/IN2P3 and Université de Nantes, 
44307 Nantes, France
Subatech began a new medical imaging technique by beneficiating from the development of 
Arronax cyclotron around the Nantes city in France. This new technique is called the 3 gam-
mas imaging. The main idea is to try to locate each decays of Sc44 radionuclide individually 
with a 3D position resolution beneath the centimeter. This breakthrough in instrumentation 
technique should be demonstrated by the help of the Xemis 1 prototype which is a high sensi-
tive liquid Xenon Compton telescope. The good properties of ultrapur liquid Xenon as detection 
medium (high atomic number, high density, high emission light and ionization yield) leads to 
a construction of a sensitive monolithic and homogeneous volume of detection with an adap-
table geometry. Thanks to an ultra low noise front end electronics operating at liquid Xenon 
temperature (around 100 electrons NEC) and a fast UV sensitive PMT, high spatial resolution 
and high energy resolution are achievable in 3D. This is particularly important for Compton 
imaging since all interactions in the medium have to be identified to reconstruct the direction 
of arrival of the gamma ray. 
A small prototype with an active area of 1’’x1’’ is now in test at Subatech and shows promising 
results with a 511keV source from 22Na. All the cryogenic system is fully operational with a high 
purification rate and shows a very good stability. A new geometry Xemis 2 is currently under 
development to adapt this imaging technique to the small animal size.
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PET/MR: THE MOLECULAR IMAGING DREAM TEAM
Piotr Maniawski
Philips Healthcare, Cleveland, Ohio
In the last decade, PET/CT imaging systems have become an essential tool for staging and 
restaging of various types of malignant tumors and has been shown to have a significant impact 
on patient management. PET/CT also shows exciting potential in predicting the response to 
treatment for several types of cancer, including metastatic breast cancer, lung cancer, lympho-
mas and others. 
The clinical and commercial success of combined PET and CT imaging modality was primarily 
driven by the complementary character of data derived from each of the imaging modalities: 
anatomical detail of the CT and metabolic, molecular level information delivered by PET ima-
ging. In addition, the clinical workflow improvement and ease of use of the combined system 
can’t be overlooked. 
Integration of CT and PET addressed some of the critical questions in diagnosis and staging 
of the disease: combination of lesions detectability (with FDG PET) and their localization (with 
CT). It also paved the way to further integration of other imaging modalities. For example, more 
and more SPECT cameras are being replaced by combined SPECT/CT systems. 
With the evolution of MR imaging techniques, MR imaging studies can provide additional dia-
gnostic information regarding soft-tissue analysis, tumor detection, tissue characterization and 
functional imaging. It is not uncommon today for oncology patients to have both a PET/CT and 
MR imaging scans providing complementary diagnostic data. In some cases, the diagnostic 
value of MR for detection and staging of cancers can be superior to CT studies, which limits the 
value of the diagnostic CT studies that can be performed in combination with the PET/CT study 
to a simple anatomical localization and attenuation correction scan. 
This promise to provide a comprehensive picture of patient anatomy (imaged by MR) combined 
with multi parameter lesion characterization (imaged by PET and advanced MR imaging tech-
niques) makes an integrated PET/MR system a leading candidate for the molecular imaging 
‘dream team’.
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CORTICAL ACTIVITY IN BILATERAL COCHLEAR IMPLANT USERS
Katarzyna Cieśla1, Julian Matthews2, Rohini Aggarwal3, Kevin Green4
1MSc, School of Psychological Sciences, University of Manchester, UK; Bioimaging Research Center, 
Institute of Physiology and Pathology of Hearing, Warsaw, Poland
2Senior Lecturer, School of Cancer Enabling Sciences, MAHSC, University of Manchester
3Research Fellow, Central Manchester University, NHS Foundation Trust
4Consultant ENT Surgeon, University of Manchester, MAHSC, Central Manchester NHS Foundation Trust
Introduction: The study aims to compare cortical changes observed in recipients of bilateral 
cochlear implants (CI) to normal hearing controls (NH) in response to simultaneous binaural 
auditory stimulation.
Materials and methods: Six adult individuals with post-lingual deafness, experienced bi-
lateral cochlear implant users, and six normally hearing volunteers participated in the study. 
All subjects had up to twelve PET scans (using [15O]H2O) in two scanning sessions on the 
same day. During each scan one of three auditory stimuli (randomised), including BKB Sen-
tences, Reversed BKB Sentences and Silence was delivered (Bench et al.1979). Images of 
the radioactivity concentration during 90 seconds following arrival of [15O]H2O in the brain 
were reconstructed (FBP, OSEM, OSEM+PSF); SPM8 software (The Wellcome Department 
of Cognitive Neurology, London; http://www.fil.ion.ucl.ac.uk/spm/ software/spm8) was used 
to perform data pre-processing and statistical analysis (factorial design). An additional 
statistical comparison with left-right flipped images served to assess any lateralisation of 
activations. Region of interest analysis (ROI) using the Automatic Anatomical Labelling 
Atlas and an in-house programme was carried out to verify the SPM findings. The following 
contrasts were employed to investigate within- and between-group effects: (1) Sentences vs. 
Silence, (2) Sentences vs. Reversed Sentences, and (3) Reversed Sentences vs. Silence. 
The study was approved by the Cumbria and Lancashire Research Ethics Committee B and 
the Administration of Radioactive Substances Advisory Committee. All participants provided 
an informed consent.
Results
Sentences vs. Silence
In subjects with normal hearing significant activations were found in bilateral superior temporal 
lobes (Brodmann’s areas [BA] 21 and 22), the left middle temporal lobe (BA 21), and the right 
superior temporal pole (BA 22) (p < 0.001, Family-wise error-corrected [FWE]). In cochlear 
implant-users bilateral middle temporal lobes were recruited (BA 21,22), as well as the left 
superior temporal pole (BA 21) and the right superior temporal lobe (BA 21) (p < 0.001, FWE). 
ROI analysis showed activations in bilateral superior temporal lobes in both groups, and bilat-
eral middle temporal lobes and superior temporal poles in cochlear implant users (p < 0.001, 
Sidak correction). 
Reversed Sentences vs. Silence
Both groups showed activations in bilateral superior temporal lobes (BA 21,22) (p < 0.001, 
FWE); patients additionally recruited bilateral middle temporal lobes (BA 21) (p < 0.001, FWE). 
Regions-of-interest approach revealed recruitment of bilateral superior temporal lobes in both 
groups and the left Heschl gyrus in normally hearing individuals (p<0.001, Sidak correction). 
Sentences vs. Silence/Reversed Sentences vs. Silence
Further voxel-by-voxel analysis revealed larger and more diffuse activations in various tem-
poral regions in CI-subjects when compared to normally hearing individuals in all three con-
trasts (p < 0.001, FWE). There was no hemispheric lateralisation found for either of the groups and 
comparisons.
Sentences vs. Reversed Sentences
 Normally hearing subjects had activations in the left-hemisphere superior temporal pole (BA 
38) and the superior temporal lobe (BA 21,38) (p = 0.008, FWE), whereas cochlear implant 
recipients recruited bilateral middle temporal lobes (BA 21) (p = 0.04 FWE on the left and 
p < 0.001 FWE on the right), middle temporal poles (BA 21) (p < 0.001, FWE), and the left 
A31www.nmr.viamedica.pl
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superior temporal pole (BA 38) (p < 0.001, FWE). Although visual inspection suggested more 
diffuse and more significant activations in the left hemisphere in both NH and CI-users, late-
ralisation analysis did not reach statistical significance. ROI approach revealed no significant 
activations in this high-level contrast 
Conclusions: Users of bilateral cochlear implants with post-lingual deafness showed to 
process speech stimuli using mechanisms similar to normally hearing individuals, engaging 
areas in bilateral temporal lobes. Activations found in the study were consistently more diffuse 
in CI-patients, compared to normally hearing controls. This might imply that recipients of 
cochlear implants require larger neuronal contribution to process speech. Left-hemispheric 
lateralisation of supra-phonological features of language (contrast Sentences vs. Reversed 
Sentences) was suggested in both groups but the analysis did not reach statistical signifi-
cance.
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SYNTHESIS AND IN VITRO AND IN VIVO EVALUATION OF NEW 
67/68GA-SEMICARBAZONE COMPLEX: POTENTIAL PET/SPECT 
TUMOR IMAGING AGENT
I Al Jammaz, B Al-Otaibi, N AlHokbany, S Okarvi 
Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Centre, 
P.O. Box 3354, Riyadh 11211, Kingdom of Saudi Arabia
Heterocyclic thiosemicarbazones, semicarbazones and their metal complexes have been 
extensively investigated as potential antitumor agents. Most studied thiosemicarbazones and 
semicarbazones were the pyridine-based compounds which might be attributed to their resem-
blance to pyridoxal metabolites that attach to co-enzyme B6-dependent enzymes and cause 
enzyme inhibition. Varieties of metallic positron emission tomography (PET) and single photon 
emission computed tomography (SPECT) radionuclides were incorporated into thiosemicarba-
zones chelates. Among these radionuclides, gallium-67/68 (67/68Ga) and copper-62/64 (62/64Cu) 
have shown considerable success for targeting tumor xenografts in athymic mouse models. 
Recently, radiolabeled 67Ga-thiosemicarbazone complex was synthesized with high radiochemi-
cal yield and purity. Biodistribution study in fibrosarcoma bearing mice revealed specific tumor 
accumulation after 2 h post injection which may suggest that 68Ga is a better candidate for 
tumor imaging than 67Ga. 
Due to the well known coordination chemistry of gallium, high stability of GaIII-semicarbazone 
complexes as well as their enhanced anti-neoblastic activity and in an attempt to develop new 
radiotracers with favorable biochemical properties, we here report the synthesis, characte-
rization and preclinical evaluation of new 67/68Ga- 2-acetylpyridine 4,4-dimethylsemicarbazone 
(67/68Ga-APSM) as a potential PET and SPECT tumor imaging agent. The synthetic approaches for 
the preparation of 67/68Ga-APSM chelates were simple and straightforward. Acetate buffer solu-
tions of 67/68GaCl3 (37–300 MBq, prepared according to well-established procedure) were reacted 
with 2-acetylpyridine 4,4-dimethylsemicarbazone dissolved in absolute ethanol (pH = 4.5). The 
reaction mixture was heated at 90oC and monitored by means of TLC and HPLC at different time 
intervals (15–60 min). Work up of these reactions gave 67/68Ga-APSM complexes in quantita-
tive radiochemical yields and purities as assessed by TLC and HPLC in less than 60 min. The 
proteolytic degradation of these complexes were determined in human plasma and revealed 
that these radiotracers remained sufficiently stable during incubation at 37oC for at least 2 h. 
In vivo biological characterizations were carried out in normal Balb/c mice, revealed rapid blood 
clearance of radioconjugates with equal excretion by the urinary and hepatobialary systems. 
Biodistribution studies in nude mice bearing tumor are in progress. 
 
Scheme 1. Synthesis of of Ga-APSM complexes (Ga=nat/67/68Ga)
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THE EVALUATION OF FLUORESCENT AND F-18 LABELLED PEPTIDE 
SEQUENCES TARGETING APOPTOTIC CELLS IN VITRO AND IN VIVO
Janice Kapty1, Melinda Wuest1, 2, Frank Wuest1, 2, John R. Mercer1, 2
1Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta
2Edmonton P.E.T. Center, Cross Cancer Institute, Edmonton, Alberta, Canada
Introduction: Programmed cell death (apoptosis) is both a natural process in organ and tissue 
development and homeostasis and a contributor to human pathology in a variety of diseases. 
In addition, the induction of apoptosis is a desired aim in cytotoxic therapies used in the clini-
cal management of cancer. Despite its importance we do not yet have a clinically acceptable, 
non-invasive imaging modality targeting apoptosis. A variety of PET imaging agents have been 
investigated for clinical imaging of apoptosis (1) but none has yet achieved the status of a routine 
agent with the required targeting selectivity and pharmacokinetic properties. Recently a series of 
hexapeptides was found to possess strong binding affinity for cell surface phosphatidylserine 
(PS) expression based on phage display analysis (2). The goal of the present study was to 
evaluate these peptides in vitro and in vivo as potential PET radiotracers. 
Methods: A series of peptides (LIKKPF, PGDLSR, CLIKKPF, CPGDLSR) were modified by 
N-terminus attachment of fluorescent 5-carboxyfluorescein (5-FAM) and evaluated in vitro 
for binding using an immobilized PS plate assay, a PS liposome cell-mimic assay and nor-
mal and apoptotic Jurkat cells. The peptides were labelled with F-18 via prosthetic group 
chemistry using N-succinimidyl 4-[18F]fluorobenzoate ([18F]-SFB) for peptides LIKKPF and 
PGDLSR and using N-[6-(4-[18F]fluorobenzylidine)aminohexyl]maleimide ([18F]-FBAM) for the 
thiol containing peptides CLIKKPF and CPGDLSR (3). The [18F]FBAM labeled peptides were 
further evaluated for binding on normal and apoptotic Jurkat cells and in small animal PET 
imaging studies using a murine EL4 lymphoma tumor model in C57BL6 mice with chemo-
therapy induced apoptosis in vivo (100mg/kg cyclophosphamide and 38mg/kg etoposide 
on two consecutive days) validated with the TUNEL assay. 
Results: In the plate-based assay all four fluorescent-labeled peptides bind with some selec-
tivity to PS relative to phosphatidylcholine (PC) with estimated KD values between 0.4–7.9 µM. 
Fluorescent labeled annexin-V (FITC) showed an estimated KD value of 6.6 nM in this assay. 
Liposomes with 10% PS/90% PC in the membrane bilayer showed fluorescence from bound 
peptides and annexin-V (FITC) by confocal microscopy while 100% PC liposomes showed no 
fluorescence. Binding of the fluorescent peptides and annexin-V (FITC) was also observed 
selectively in apoptotic Jurkat cells. Radiolabelling of the hexapeptides LIKKPF and PGDLSR 
with the prosthetic group [18F]-SFB led to only low radiochemical yields (< 20%) due to poor 
reactivity and lack of chemoselective attachment to the terminal amine group. The cysteine 
modified heptapeptides CLIKKPF and CPGDLSR on the other hand were radiolabelled at 
high radiochemical yield (> 95%) and chemoselectivity at the thiol group of the terminal 
cysteine when reacted with [18F]-FBAM. The [18F]-FBAM labelled peptides showed binding 
to normal Jurkat cells ([18F]-FBAM-CLIKKPF 7.6 ± 2.0 and [18F]-FBAM-CPGDLSR 1.6 ± 0.8 
%ID/mg protein (n = 3) after 15 min), which increased in apoptotic Jurkat cells (16.7 ± 2.2 
(p < 0.05) and 3.3 ± 2.4 %ID/mg protein).
Mouse biodistribution studies in tumor mice were unremarkable, exhibiting rapid blood clearance 
and shared excretion by hepatobiliary and renal routes. Both [18F]-FBAM labelled peptides were 
analyzed by 60 minute dynamic small animal PET. In untreated EL4 tumors [18F]-FBAM-CLIKKPF 
showed an initial uptake resulting in a standardized uptake value (SUV3min) of 0.51 ± 0.04 which 
decreased to 0.13 ± 0.01 (n = 3) after 60 min. F or muscle tissue SUV3min 0.29 ± 0.04 and 
SUV60min 0.09 ± 0.01 was determined. [
18F]-FBAM-CPGDLSR possessed lower EL4 tumor uptake 
levels: SUV1min 0.35 ± 0.02, SUV3min 0.17 ± 0.02 to SUV60min 0.06 ± 0.01 (n = 3). In apoptotic 
EL4 tumors no significant difference in radioactivity uptake profile was observed for either [18F]-
FBAM-labelled peptides. The poor targeting may in part be due to the relatively rapid metabolism 
of both radiolabeled peptide sequences in vivo as determined in mouse plasma by radio-TLC 
(1 to 25% intact after 15 min). 
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Conclusions: These studies have examined the first peptide-based probes designed for PET 
imaging of apoptosis. While the chosen peptide sequences show promise in in vitro studies, 
retaining their selective binding ability toward PS, they did not accumulate in apoptotic mouse 
tumors in vivo. Future studies to identify PS binding peptides stabilized against enzymatic 
degradation are warranted. 
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DEVELOPMENT OF NEW PET RADIOPHARMACEUTICALS BASED 
ON 68GA FOR DIAGNOSIS AND MONITORING OF THE THERAPEUTIC 
RESPONSE
D Niculae, I Esanu, I Ursu, P Albu
Horia Hulubei, National Institute for Physics and Nuclear Engineering (IFIN-HH), Department 
of Radioisotopes and Radiation Metrology, Magurele, Ilfov, Romania
68Ge/68Ga generators provide cyclotron-independent access to positron emission tomography 
(PET) radiopharmaceuticals. The 270 days half-life of the parent allows the use of the genera-
tor for a long period, potentially up to 1 year or even longer. The 68 min half-life of the 68Ga 
matches the pharmacokinetics of many peptides and other small molecules owing to rapid 
diffusion, localization at the target and fast blood clearance. The 68Ga solutions eluted from 
a tin dioxide based generator are usually containing small amounts of other cations (metallic 
impurities such as Fe, Zn, Ge, Sn) and should be purified prior the radiolabelling of peptides but 
fractionated elution could also be used for synthesis, when short reaction time is needed and 
further purification is envisaged. The elution profile and yield was followed over 1 year. The elution 
yield is highly dependent on HCl concentration; 0.6 M HCl was used for elution (yield > 75%) 
followed by 5–7 mL 1M HCl washing. Ge-68 content in the eluate was less than 0.002% over 
1 yr. The solution of Ga-68 coming from generators is in stable chemical form, cation Ga(III), which 
can precipitate and hydrolysis at pH 4–7 in the insoluble form, trihydroxide, if the concentration 
exceeds the nanomolar level. Ga(III) is suitable for the complexation with chelates conjugated 
with peptides. The purified eluate was used for radiolabelling of DOTA-VIP. The radiolabelling 
parameter were establish, the most critical being pH (3.8–4), temperature (95–100°C) and the 
buffer (only non-ionic buffers should be used).
The results obtained after fractioned elution and the purification of eluates on a cation exchange 
column, anion exchange column or combining a cation and an anion exchanger of a tin dioxide 
based 68Ge/68Ga generator are presented. All this methods for concentration and purification are 
feasible, but each of them is presenting some advantages over the others. Fractionated elution 
leads to the concentration of the most the activity (80–95%) in a small volume, 1.5–2 mL but no 
purification is done. The purification using a cation exchanger leads to 60–80% recovery percentage 
of 68Ga and the process took 35 minutes but this process involves the use of acetone. The recovery 
of gallium-68 from the anion exchanger column in 1 mL water was 84–90%, the process is taking 
less than 30 min but the iron separation remains an issue. By combining the cation and anion ex-
change processes, 90–94% of the uploaded activity was recovered but the process took 40 min. 
Depending of the eluate postprocessing method the radiolabelling of DOTA-VIP yield was 60–80% 
(A), 10–40% (C) 50–70% (C+A) while the radiochemical purity of 68Ga-DOTA-VIP, after SPE purifica-
tion was 96, 92% and 95% respectively. 
We also present the preliminary evaluation of an organic matrix based 68Ge/68Ga generator, 
its elution profile and yield. The generator was eluted daily, eluent 0.05 M HCl, 1 mL/min; the 
yield was ranged between 66–93% (10 elutions), average 78%. The elution profile show about 
70% of the activity was found in 2 mL eluate and up to 90% in 3 mL.
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THE ENVISION PROJECT
Manuela Cirilli, Manjit Dosanjh (on behalf of the ENVISION collaboration)
CERN, 1211 Geneva 23, Switzerland
Hadron therapy is a highly advanced technique of cancer radiotherapy that uses beams of 
charged particles (ions) to destroy tumour cells. While conventional X-rays traverse the human 
body depositing radiation as they pass through, ions deliver most of their energy at one point. 
Although hadron-therapy with protons and light ion beams was proposed for the treatment of 
cancer sixty years ago, its clinical implementation has been slow, and only since the 1990’s have 
hospital-centred multi-room treatment facilities existed with vertical beam lines and rotating 
gantries suitable for clinical therapy.
To date, protons and carbon ions have been used to treat about 80.000 and 8.000 patients re-
spectively and the number of hospital-based multi-room centres either running or in construction 
is almost thirty centres worldwide. Moreover, seven companies offer turn-key solutions featuring 
either proton or carbon ion accelerators, the associated beam transport lines and treatment 
rooms - equipped with moving beds and precise alignment systems, and sophisticated treat-
ment planning systems (TPSs).
The conventional methods for the assessment of patient positioning used in X-ray based radia-
tion therapy rely on the transmission of a non-negligible fraction of the treatment beam through 
the patient. This allows for the simple reconstruction of patient position based on bony anatomy 
or fiducial markers. Such techniques are not applicable in hadron-therapy, whose remarkable 
advantage is that the energy deposited by a pencil hadron beam increases in front of the target 
and, after the “Bragg peak”, sharply decreases behind the target, where almost no exit dose 
(for protons) or a small dose (for carbon ions) is deposited.
Hadron therapy is most advantageous once the position of the tumour is accurately known, so 
that healthy tissues can be protected. In addition, accurate positioning is a crucial challenge for 
targeting moving organs and for adapting the irradiation as the tumour shrinks with treatment. 
Therefore, quality assurance becomes one of the most relevant issues for an effective outcome 
of the cancer treatment.
In order to improve the quality assurance tools for hadron therapy, ENVISION is developing 
solutions for:
— real-time non invasive monitoring;
— quantitative imaging;
— precise determination of delivered dose;
— fast feedback for optimal treatment planning;
— real-time response to moving organs;
— simulation studies.
Striving for precision
Positron Emission Tomography (PET) is the only physiological real-time non-invasive monitoring 
tool available. During charged particle therapy, radioactive isotopes do not have to be injected, 
as is the case for normal PET imaging, since they are naturally generated in the irradiated tissues. 
The radioactive isotopes emit positrons that interact with tissues producing a pair of photons. 
The PET detector looks for two almost simultaneous photons to identify the origin of the positron.
Each photon needs a certain time, called Time-Of-Flight, to travel from the emission point to the 
detector. A fast and accurate measurement of the TOF difference between the two photons al-
lows to better pinpoint the origin of the initial radiation, and therefore to improve the quality of 
the image.
A second promising way to better monitor the dose in real time is the detection of single pho-
tons and charged particles emitted almost instantaneously in the irradiated tumour.
These methods require the development of innovative detectors and dedicated recording elec-
tronics, both tackled by ENVISION.
Moving targets
In the field of cancer diagnostics, a major advance over still imaging is represented by PET cou-
pled with a new technique called Four- Dimensional Computer Tomography (4DCT): this cutting 
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edge technology allows to capture the movement of organs as well as the changes in position 
and shape of the tumour. 4D PET/CT has a huge potential to improve the current tools used 
to compensate for organ motion during irradiation. ENVISION explores the feasibility and the 
clinical relevance of 4D PET/CT application for hadron therapy, and develops innovative tech-
nologies and methods for optimizing the quality of the images acquired.
Towards a global treatment planning
ENVISION’s ultimate goal is to use the wealth of information provided by these novel imaging 
techniques to optimise treatment planning. This is an essential step to bring the technology out of 
the research environment and into the clinical world. ENVISION will develop tools to automatically 
analyse real-time monitoring images and use the information gathered to give feedback on how to 
continue the treatment. Since different treatment sites have different set-ups, ENVISION is aiming 
to develop and build portable devices to measure the specific characteristics of each site and use 
them to fine-tune the therapy.
Models needed
Accurate numerical simulations are needed by all ENVISION tasks to optimise the design of the 
detectors, to develop software that can reconstruct the dose map from the images collected, and 
to assess the accuracy of real-time dose monitoring. ENVISION will implement full simulations of 
the detailed physics processes that lead from the dose deposition to the recorded image. A fast 
dedicated simulation tool suitable for use in treatment planning is also being implemented.
The ENVISION project just entered the second half of its 4-year funding, and all the R & D activi-
ties produced first encouraging results which will be discussed in this talk.
Acknowledgement: The abstract is submitted on the behalf of the ENVISION project, which 
is co-funded by the European Commission under FP7 Grant Agreement No 241851.
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[18F]FDG PRODUCTION FACILITY AT THE JOINT RESEARCH 
CENTRE CYCLOTRON (ISPRA SITE — ITALY)
K Abbas1, F Simonelli1, N Gibson1, U Holzwarth1, A Pecorale2, F Barberis Negra2
1European Commission, Joint Research Centre, Institute for Health and Consumer Protection, 
Via E. Fermi 2479, T.P. 500, 21027 Ispra (VA), Italy
2GE Healthcare, Via Galeno 36, 20126 Milano, Italy 
Abstract
Nuclear Medicine has been a fundamental tool for many years for cancer treatment. In recent 
times, Positron Emission Tomography based on the cyclotron-produced radiotracer 18F has sig-
nificantly contributed to the development of medical imaging in oncology, and combined with 
CT scanning (PET- CT) has become one of the more widely used medical technologies. The 
Joint Research Centre (JRC) Cyclotron of the European Commission (Ispra site) is one of a very 
limited number of such research facilities in the EU. Its characteristics allow the production of 
a wide range of radioisotopes and its seven beam-lines make possible the setting up of many 
different experiments. This allows it to support research in many different areas, the most im-
portant of which at the present time is research for policy development regarding the new field 
of nanotechnology.
The JRC Cyclotron is a Scanditronix MC40 model with variable energy. It accelerates protons, 
deuterons, alphas and Helium-3 ion particles. For protons, the maximum energy is 40 MeV and 
the maximum extracted current is 60 µA.
The JRC Cyclotron is successfully used for routine [18F]FDG production in compliance with the 
Marketing Authorization under a commercial partnership between JRC and General Electric 
Healthcare (GE HC). The commercial production has been operational since April 2004 without 
any significant interruption. This radiopharmaceutical site has been the first producing centre 
authorised in Italy. About 18F production, the cyclotron is running every night for about 6 hours. 
The [18F]FDG radiopharmaceutical is distributed to hospitals and diagnostic centres in the north 
and central regions of Italy. The radiopharmaceutical is commercially recorded under the brand 
name SteriPET. This commercial activity does not interfere with other research projects that 
normally take place during daytime working hours. 
As regards to [18F]FDG commercial production, JRC is responsible for 18F supply and for ra-
dioprotection support while GE HC is responsible for the [18F]FDG synthesis and distribution 
to hospitals. The production facility is located inside the controlled area of the cyclotron buil-
ding. It comprises the target for 18F-Fluoride production, two automated synthesis modules and 
an automated dispensing unit, installed in three separate hot-cells. The quality control of the 
produced [18F]FDG is carried out according to the SteriPET Marketing Authorization. GE HC, 
after the radiopharmaceutical site of Ispra, has developed other 3 production facilities around 
Italy in collaboration with national research centres or private companies.
The complete [18F]FDG production facility, being located in the cyclotron controlled area (radio-
protection regulations), is in depression with respect to the atmosphere. The Clean Room where 
the [18F]FDG is synthesised and sterilised is in over pressure with respect to other areas of the 
facility (pharmaceutical regulations). The two synthesis modules and the [18F]FDG dispenser 
unit are fully controlled and monitored by computers. In the area dedicated to QC all instru-
ments and equipment are automated.
A synthesis cycle is accomplished in about 35 min. The preparation of the synthesis module 
does not exceed 15 min. After synthesis, the radiopharmaceutical is transferred to the dispens-
ing unit by helium pressure. The yield of [18F]FDG is around 75% (decay-corrected).
In the dispensing unit, a final sterilisation cycle is performed. Up to 17 vials of [18F]FDG can 
be dispensed and sterilised in a single production run. The dispensing process is based on 
dispensing under laminar flow and sterilisation in the final vials with steam at 135°C. The dispen-
sing process lasts a maximum of 30 min depending on the number of vials. After sterilisation, 
vials are remotely inserted in lead containers inside the hot cell and then transferred through 
a pass through box into the shipment room. The software of the synthesis module, dispenser and 
QC equipment are also designed according to GMP guidelines and all relevant parameters are 
recorded and stored and can be reviewed at any time. 
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Quality controls on the product is carried out according to the SteriPET Marketing Authoriza-
tion where the specifications of the product as a radiopharmaceutical are presented. About 
30 minutes are necessary for completion of those quality controls required for the release of the 
radiopharmaceutical. Radionuclide, chemical and radiochemical purity controls are carried out. 
The [18F]FDG can be released before completion of the biological analysis. As regards to the 
site production efficiency, the annual production plan for the period March 2011 – March 2012 
was defined and approved. Over this period, more than 400 productions were carried out, in 
which 260 GBq/run of 18F have been produced.
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THE PLAN AND DESIGN OF A GMP PET FACILITY: 
CHALLENGES AND PITFALLS
C Gameiro1, J M Geets1, D Blampain1, F Devillet1, H Prpic2, H Amaral3, A Amaral3
1Ion Beam Application (IBA), Louvain la Neuve, Belgium
2Ruđer Medikol Cyclotron Ltd., Zagreb, Croatia
3 PositronPharma S.A., Santiago, Chile
Radiopharmaceuticals (RP) are a group of human parenteral medicines that are regulated by 
a number of directives and regulations. Most of these rules do not consider the special character 
of RPs such as the short half-life, small scale preparation, parametric release (no guarantee of 
sterility), low toxicity of the final product besides the radiation issues. In addition, the regulatory 
environment is still not harmonized at the worldwide level leading to different local interpreta-
tions and misunderstandings. 
The scope of the facility may range from a dedicated product to a multipurpose site that manu-
factures various RPs for commercial and/or clinical and/or research applications (categories I-V) 
[1]. Irrespective to the type of facility crucial factors have to be considered: the current regulatory 
climate for PET drug production [GMP (Good Manufacturing Practice], industrial hygiene and 
radioprotection); radiation safety issues; effective production flow (i.e. optimization between the 
space, people and material flow); sufficient and qualified personnel [2, 3]. A primary element 
to be prepared is a complete risk assessment covering the GMP risks as well as the operator 
and public safety. This evaluation may impact final layout and design as well as the scope and 
type of equipment and procedures required.
A detailed project design is then compiled for a tender call to local building companies. In 
this file, complex items such as radiation protection; Heating Ventilation Air-conditioning 
system (HVAC) system and clean rooms and the utilities (electricity, water, gases, etc) have 
to be included. Most importantly, besides the cyclotron, other equipment such as shielded 
cells, synthesizers, dispensing systems, quality and radiation monitoring equipment should 
be integrated into the pharmaceutical classified environment which is within the radiation 
controlled area. User Requirement Specifications (URS) are required for all the equipment 
and installations, and should be agreed upon between project leader and end-user. A set of 
documentation has to be prepared including radiation protection and pharmaceutical-related 
protocols and procedures (validation master plan; site master plan; installation, operation, 
performance qualification; standard operating and working procedures etc...). Staff training 
and education are essential GMP requirements as well as the qualification and validation 
work of the facility and of critical equipment before applying for the pharmaceutical certifi-
cation and market authorization (if applicable).
Due to their complex and multidisciplinary nature such endeavors may fail for several reasons. 
The first one is the lack of a task force in place where the stakeholders and experts in all related 
disciplines are put together to evaluate the feasibility and viability of the project at the begi nning. 
Second reason for failure is to select a company without a track record of projects of the same 
kind or to choose the smallest budget without considering the extent of the work. Another frequent 
cause of failure is the poor definition of the goals of the PET Center which will create frustration, 
delays and over cost. Extra space should then be provisioned for future developments rather 
than adding it later at higher cost. Another point not to be neglected is the need for a centralized 
project management to coordinate the various suppliers working as an interface in all aspects of 
the project and dealing with the construction, the delivery and installation schedule.
In conclusion, global support and availability of company experts during the construction, 
installation and commissioning phases are fundamental elements for a successful project. All 
the required documentation for the licenses, qualification and validation support as well as the 
training program must be clearly discussed in the global scope of the project to avoid delays. 
Having real experts around the table will ensure design with efficient flow of people, material, 
waste and enough ergonomic for the operation leading to project achievement on budget and 
on time within the restrictive regulatory environment for PET RPs production.
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ESTABLISHING A PET RESEARCH CENTER IN ZAGREB, CROATIA. 
STATUS AND PROGRESS REPORT
Alfred Švarc 
Rudjer Boskovic Institute, Zagreb, Croatia
Completion and opening of a commercial FDG production facility at Rudjer Boskovic Institute, 
Zagreb, Croatia ensured a continuous, reliable daily supply of radioactive compound at site. 
This has laid foundations for establishing a Centre for nuclear molecular diagnostics which first 
uses already available FDG, but later we also plan to synthetize other F18 radiopharmaceuticals. 
In the long run it is anticipated that we shall expand our activities to other positron-emission 
isotopes like C11. A ClearPet camera has been purchased, delivered, tested and correlated 
with PMOD image analysis software. We report on the present operational status of facility, we 
show first preliminary results, and offer our projections for further development in scientific and 
organizational sense. The final aim of this facility is to grow into a strong research center with 
good scientific collaboration with other R & D organizations of the region. 
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PRECLINICAL METABOLIC IMAGING WITH PET TO MONITOR 
TUMOUR RESPONSE TO THERAPY
Dmitry Soloviev, David Lewis, Kevin Brindle
Cambridge Research Institute, Cancer Research UK, Li KaShing Centre, Robinson Way, CB2 0RE, 
Cambridge, United Kingdom
Introduction: Preclinical PET imaging can be used in different ways to facilitate translational 
research. However, there are many challenges in introducing micro PET imaging into practice. 
In the present work we give examples of how we have used a micro PET/CT imaging facility in 
a cancer research institute. 
Methods: Metabolic substrates available from the clinical PET programmes were used to monitor 
response to different types of anticancer therapy in genetically modified spontaneous mouse 
cancer models as well as in tumour xenografts. [18F]FDG and [11C]acetate were injected intrave-
nously and images acquired using a nanoPET/CT (Mediso, Hungary) preclinical scanner. Data 
were acquired in list mode and reconstruction was performed with proprietary Nucline software 
using the OSEM algorithm provided by the scanner manufacturer. To process the images we 
used the InVivoScope software package (Bioscan). Regions of interest were drawn around 
the tumour based on athresholding method (25, 50 and 75% of the maximum intensity voxel). 
Standard Uptake Values were calculated for all thresholds, as well as the SUVmax.
Results: Changes in tumour tracer accumulation before and after treatment could be moni-
tored by the nanoPET/CT scanner. Standard Uptake Values calculated for regions of interest 
incorporating all voxels at the 75% threshold represented the most robust readout to monitor 
changes in tumour metabolism after anticancer treatment.
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PET-CT EVALUATION OF SOLITARY PULMONARY NODULES: 
WITH OR WITHOUT A RADIOLOGIST? 
Andrea d’Amico1, Cesary Przeorek1, Jolanta Siewińska1, Kamil Gorczewski1, Izabela Szopa1, 
Joanna Sczasny2, Maria Turska-d’Amico3, Katarzyna Steinhof-Radwańska2, 
Barbara Bobek-Billewicz2, Jarosław Kużdżał4
1Diagnostic PET Department, Comprehensive Cancer Centre, Maria Sklodowska-Curie, Memorial Institute 
Branch Gliwice, Gliwice, Poland 
2Radiodiagnostics Department, Comprehensive Cancer Centre, Maria Sklodowska-Curie, Memorial 
Institute Branch Gliwice, Gliwice, Poland
3Department of Oncological and Reconstructive Surgery, Comprehensive Cancer Centre, Maria 
Sklodowska-Curie, Memorial Institute Branch Gliwice, Gliwice, Poland
4Department of Thoracic Surgery, Jagiellonian University, John Paul II Hospital, Cracow, Poland
Introduction: Detection of radiological changes in the lungs during routinely performed 
tests is very common.
CT scan provides information about the anatomy and morphology, may confirm whether the 
change is single or has multifocal character and may suggest the probability of malignancy. 
The radiological criteria of benignity are: central location, concentric calcification, round shape, 
no growth after 2 years of observation in CT; malignant changes are usually characterized by 
indistinct, blurred boundaries, irregular shape and peripheral location. 
Due to increased metabolism, at PET examination malignant tissues usually show a greater 
uptake of 18F-FDG than benign changes and healthy tissue. A meta-analysis by Gould et al. 
confirmed that PET with 18F-FDG is an accurate, noninvasive method for diagnosis of SPN, 
with an overall sensitivity of 96.8% and specificity of 77.8%. 
In several cases, PET-CT is described only by a specialist in nuclear medicine without consul-
ting a radiologist.
The aim of this study is to evaluate the accuracy of PET with assessment performed by a single 
nuclear medicine specialist and shoulder-to-shoulder assessment by both nuclear medicine 
and radiology specialists. 
Materials and methods: PET-CT was performed in 58 consecutive patients referred from De-
partment of Thoracic Surgery from John Paul II Hospital in Cracow because of radiologically 
diagnosed solitary pulmonary nodule (SPN) with diameter > 1 cm.
An histopatological specimen was obtained in 37 patients, by thoracothomy (36 patients) or 
transthoracic needle biopsy (1 patient). Seven patients had  metastatic lesions at PET and did 
not undergo further invasive procedures. In the remaining 21 patients a histopathological speci-
men was not obtained for other reasons. 
PET-CT tests were performed by using hybrid tomographs: Philips Gemini GXL (20 patients) or 
Siemens mCT (17 patients). 
In 17 cases PET-CT images were evaluated by a single nuclear medicine specialist (group A), 
while for the remaining 20 cases, the image evaluation was performed shoulder-to-shoulder by 
a nuclear medicine specialist and a radiologist (group B). 
Analysis of data: Overall PET sensitivity, specificity, positive and negative predictive value and 
accuracy were calculated on the basis of anatomopathologic results. These data were also 
calculated separately for groups A and B.
Results: The histopatologic examination demonstrated the non neoplastic character of 7/37 
lesions (1 fibrotic nodule, 1 sarcoidosis, 2 hamartomas and 3 inflammatory nodules), while 
other lesions had neoplastic nature.
Group A, group B and overall values  of sensitivity, specificity, accuracy,  positive and negative  
predictive values are shown in Table 1.
Discussion: Our data are consistent with the data reported in the literature. The value of the 
diagnostic accuracy was approximately 90% for all the groups, without statistically significant 
differences. 
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The lowest sensitivity and negative predictive values were found in group A (study described 
only by a specialist in nuclear medicine), while in this  group the highest specificity was ob-
served. This fact is probably due to the reluctance of nuclear medicine specialist to refer “cold” 
lesions as positive, even in presence of  radiological findings of malignancy. On the other hand, 
the accuracy was similar in both A and B groups.
It is worth signalizing that several radiological changes caused by inflammation, emphysema, 
atelectasia or tuberculosis do not necessarily affect the metabolic image, but may be important for 
the referring doctor. An accurate radiological report gives a large amount of important information 
to the referring doctor, which will not be necessarily reported by the nuclear medicine specialist.
Conclusion: PET-CT is an accurate diagnostic method to assess the nature of solitary pulmonary 
nodules. The consultation with radiologist does not substantially affect the PET-CT diagnostic 
accuracy, but can lead to a higher negative predictive value. 
Table 1 
Sensitivity Specificity PPV NPV Accuracy
Overall 90% 85.7% 96.6% 66.6% 89.1%
Group A 85.7% 100% 100% 33.3% 88%
Group B 92.8% 83.3% 92.8% 83.3% 90%
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PROGNOSTIC IMPORTANCE OF 18F-FDG UPTAKE PATTERN 
OF HEPATOCELLULAR CANCER PATIENTS WHO RECEIVED SIRT
Ozlem N Kucuk1, Cigdem Soydal1, Mine Araz, Sadik Bilgic2, Erkan Ibis1
1Ankara University, Medical School, Department of Nuclear Medicine
2Ankara University, Medical School, Department of Radiology
Aim: Aim of the study is to evaluate the effect of 18F-FDG uptake pattern of liver lesions to 
treatment response of patients who received Y-90 selective internal radiation therapy (SIRT) for 
Hepatocellular Cancer (HCC).  
Material and method: Nineteen patients (5F, 14M, mean age: 64.5 ± 14.7 years old, range: 
57–73 years) who received SIRT treatment in our department for HCC between 2008 June 
and 2011 May were included in the study. All the patients have undergone 18F-FDG PET/CT 
before SIRT because the evaluation of disease stage and metabolic activities of liver lesions. 
Patients were divided into three groups according to FDG uptake patterns of primary liver le-
sions (hypoactive, nonhomogeneous, intense). Progression free survival times (PFS) of each 
group were analyzed. Disease progression criteria were accepted as increase in tumor volume, 
progressive elevation of serum AFP levels and detection of extent metastases. Kaplan-Meier 
analysis was used for comparison of PFS times.
Results: Treatment has been given right and left lobes of liver in 18 and 1 patient respectively. 
The mean treatment dose was estimated as 1.4 ± 1.0 GBq. While liver lesions of 4 patients were 
hypoactive in pretreatment 18F-FDG PET/CT, liver lesions of 6 and 9 patients had nonhomoge-
neous and intense FDG uptake, respectively. Mean PFS time of patients who had hypoactive 
liver lesions was 5.25 ± 1.52 months. In patients who had liver lesions with nonhomogene-
ous uptake, mean PFS time was 12.3 ± 2.6 months. Lastly, in patients with intense uptake in 
liver lesions, PFS time was calculated as 19.8 ± 5.0 months. Difference between each group 
was statistically significant (p: 0.017).
Conclusion: 18F-FDG uptake pattern of liver lesions is an important prognostic factor in the 
prediction of PFS of patients who received SIRT for primary HCC.
